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Abstract
Background: Reprogramming human somatic cells to pluripotency represents a valuable resource for the development of
in vitro based models for human disease and holds tremendous potential for deriving patient-specific pluripotent stem cells.
Recently, mouse neural stem cells (NSCs) have been shown capable of reprogramming into a pluripotent state by forced
expression of Oct3/4 and Klf4; however it has been unknown whether this same strategy could apply to human NSCs, which
would result in more relevant pluripotent stem cells for modeling human disease.
Methodology and Principal Findings: Here, we show that OCT3/4 and KLF4 are indeed sufficient to induce pluripotency
from human NSCs within a two week time frame and are molecularly indistinguishable from human ES cells. Furthermore,
human NSC-derived pluripotent stem cells can differentiate into all three germ lineages both in vitro and in vivo.
Conclusions/Significance: We propose that human NSCs represent an attractive source of cells for producing human iPS
cells since they only require two factors, obviating the need for c-MYC, for induction into pluripotency. Thus, in vitro human
disease models could be generated from iPS cells derived from human NSCs.
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Introduction
Numerous laboratories have demonstrated that human and
mouse somatic cells can be reprogrammed into pluripotent stem
cells or iPS cells by the forced expression of a characterized set of
transcription factors (Oct4, Sox2, c-Myc, Klf4, Nanog, and Lin28)
in various combinations [1–10]. Oct4, Sox2, c-Myc, and Klf4 were
the four original factors that were capable of converting mouse and
humanfibroblastsintoiPscells[1,3,5,11,12].More recently,murine
liver, stomach [8], lymphocyte, b[13], and murine neural stem cells
(NSCs) [14–16] were also capable of iPs induction. Since murine
NSCs already express high levels of Sox2 [14–16], it was tested
whether these cells could be reprogrammed into iPS cells by only a
few critical factors. Indeed, it was shown that Oct4 and Klf4 could
reprogram murine NSCs at an efficiency of 0.11%, similar to the
reprogramming rate of murine fibroblasts with the original four
factors with antibiotic selection [14]. More recently, the forced
expression of Oct4 alone was shown sufficient to reprogram murine
NSCs, albeit at a low efficiency of 0.014% [15]. Since murine NSCs
have been ‘‘primed’’ with several of the factors originally discovered
to reprogram fibroblasts into iPS cells, they represent an attractive
source of starting material for iPS cell induction studies.
Here we tested whether human NSCs could be reprogrammed
into iPS cells utilizing a similar strategy as described above since
they represent a more clinically relevant source of cells for basic
studies and modeling human disease. Human NSCs can be
isolated and cultured from fetal, adult, as well as post-mortem
brain tissues, and can differentiate into astrocytes, oligodendro-
cytes, and neurons [17,18]. Similar to murine NSCs, human NSCs
also express high levels of SOX2 and may therefore only require a
limited set of factors for induction into pluripotency. Here we show
that human NSCs indeed can be reprogrammed into iPS cells by
ectopic expression of OCT3/4 and KLF4. Furthermore, we have
demonstrated by several rigorous methods that human NSC-
derived iPS cells are molecularly identical to hESCs.
Materials and Methods
Cell culture and differentiation
Fetal human NSCs, isolated from the frontal brain cortex of a
28 week term fetus, (SCP-27, P1) were obtained from the National
Human Neural Stem Cell Resource (NHNSCR, Orange, CA).
Proliferating cells were cultured in DMEM/F12 supplemented
with 1% N2 (Invitrogen, Carlsbad CA), 10% BIT-9500 (Stem
Cell), 1% penicillin, streptomycin, amphocterin cocktail, EGF
(20 ng/ml, Peprotech), and FGF-2 (20 ng/ml, Peprotech). Cells
were grown on polyornithine and laminin coated dishes and
passaged 1:2 with PBS++ (PBS with 1% BSA). All experiments
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differentiate NSCs into neurons, proliferating media was replaced
with a similar media as described above without growth factors
and supplemented with all-trans Retinoic acid (Sigma) at 2 uM
and forskolin (Sigma) at 5 uM. To induce astrocytic differentia-
tion, NSCs were cultured in DMEM/F12 supplemented with 1%
N2 and 10% fetal bovine serum. Oligodendrocyte differentiation
was induced by culturing the cells in DMEM/F12, 1% N2, and
IGF-1 (200 ng/ml). In all conditions, cells were allowed to
differentiate for 1 week.
The UC06 (HSF6) human ES cell line (P62) was obtained from
the National Stem Cell Bank (NSCB), and the adipose derived
mesenchymal stem cell (AD-MSC) line was generously obtained
from Dr. Jeffrey Gimble from the Penington Biomedical Research
Institute.
To induce mesoderm and endoderm lineages from iPS cells,
cells were grown as embryoid bodies (EB) in DMEM/F12 with
10% fetal bovine serum for 2 weeks. EBs were then plated to 12
well culture dishes to allow them to adhere to form a monolayer.
To induce ectoderm formation, EBs were cultured in DMEM/F12
and 1% N2 supplemented with retinoic acid (2 uM) and forskolin
(5 uM).
Viral production and human iPS induction from human
NSCs
Retroviral vectors containing cDNAs for OCT3/4 and KLF4
were obtained from Addgene (Cambridge, MA) and transfected,
along with packaging plasmids CMV Gal-Pol and VSVG, into
human embryonic kidney carcinoma 293 cells (HEK-293) using
the CaCl2 transient transfection method. Supernatants were
collected for 3 consecutive days beginning 48 hours after
transfection. Virus was concentrated by centrifugation at
90,000x g for 2 hours at 4uC, and resuspended in 200 ml PBS.
Viral titers were determined to be approximately 10
8 viral
particles/ml based on immunocytochemical analysis. 10
6 human
NSCs (passage 10) were infected with retroviruses encoding
OCT3/4 alone or OCT3/4 and KLF4 at an MOI of 10 in human
NSC media. In two-factor reprogramming experiments, 80% of
cells were infected with both OCT3/4 and KLF4. Similar
targeting efficiencies were obtained when OCT3/4 was trans-
duced alone.
Bisulfite sequencing
DNA was isolated from human NSCs, ESCs and iPS cells and
treated with bisulfite using the EpiTect Bisulfite Kit (Qiagen)
according to manufacturer’s instructions. Amplified products were
purified using gel filtration columns (Qiagen), cloned into the
pCR2.1-TOPO vector (Invitrogen), and sequenced with M13
forward and reverse primers.
Alkaline phosphatase staining
Alkaline phosphatase staining was performed with the Alkaline
Phosphatase Detection Kit (Millipore) according to manufacturer’s
instructions.
qPCR and RT-PCR analysis
RNA was harvested from proliferating HSF6 hESCs (P67) and
MSCs (P10). Total RNA was reverse transcribed with RT
2 First
Strand Kit (SABiosciences) according to the manufacturer’s
instructions. Primer sequences are listed in Table S1. Real-time
quantitative PCR reactions were performed using RT
2 Real-Time
SYBR Green/Rox PCR Master Mix (SABiosciences) and run on
an RT




5 minutes, and then blocked with 10% donkey serum with 0.1%
Triton X-100. All primary antibodies were diluted in blocking
solution and incubated overnight at 4uC. Primary antibodies
utilized are listed in Table S1. Nuclei were counterstained with
DAPI. All images were captured using a Zeiss LSM510-META
confocal laser-scanning microscope (Zeiss, Thornwood, NY).
Teratoma analysis
Teratomas were generated from iPS clones 1 and 3 by
subcutaneous injection of 1610
6 cells into the dorsal flank of
isoflurane-anesthetized athymic nude mice (Jackson Labs). Terato-
mas were recovered 3–4 weeks post-injection, fixed for 24 hours in
10% formalin, embedded in paraffin, and sectioned at a thickness of
10 mM. Sections were stained for hematoxylin and eosin.
Karyotype analysis
Karyotyping of human NSC-derived iPS lines was performed at
the Molecular Cytogenetics shared resource at the Ohio State
University Comprehensive Cancer Center. Karyotyping was
performed on iPS lines 1 and 2.
Results
Human NSCs Express Genes Associated With
Pluripotency
ESCs are maintained in a state of pluripotency by a precise
regulation of numerous intrinsic and extrinsic factors. In hESCs,
Fibroblast growth factor (FGF), activin, and Bone morphogenetic
signaling (BMP) signaling have been shown to be critical in
maintaining self-renewal [19]. In addition, intrinsic factors such as
OCT3/4, SOX2, and NANOG are generally regarded as the
central core of genes that keep hESCs in an undifferentiated state
capable of indefinite self-renewal [20].
In contrast, hNSCs differ greatly from hESCs in their growth
properties, differentiation potential, and gene expression profile.
As shown in 1A, similar to hESCs, hNSCs express high levels of
SOX2, which is considered a key regulator of pluripotency [19],
and NESTIN, a protein specific to NSCs [21–23]. Human NSCs
have been generally considered to have limited differentiation with
the capacity to differentiate into only neurons, astrocytes, and
oligodendrocytes under permissive conditions, as we have
observed (Figure 1B–D). In addition, the self-renewal capacity of
hNSCs is more limited than hESCs [17]. To further investigate
additional similarities between hNSCs and hESCs at the
transcriptional level, we analyzed the expression of key genes
involved in hESC self-renewal and pluripotency utilizing semi-
quantitative RT-PCR analysis. As shown in Figure 1E, all key
genes involved in maintaining pluripotency were expressed in
hESCs, as expected. In contrast, hNSCs were shown to express a
more limited subset of factors, which included SOX2, c-MYC,
and KLF4. To quantitatively determine differences between the
expression levels of these genes in hNSCs and hESCs, we utilized
real time RT-PCR. Our results showed that hNSCs express 1.4
fold higher levels of SOX2, fourfold lower levels of c-MYC, and
threefold lower levels of KLF4 relative to hESC expression levels.
In comparison, mouse NSCs were reported to express twofold
higher levels of Sox2, an eightfold lower level of Klf4, and a
tenfold higher level of c-Myc expression relative to mouse ESC
expression levels [14].
iPSCs from Human NSCs
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expression to a much larger scale to potentially identify similar
signaling cascades that might be conserved between hNSCs and
hESCs. We utilized quantitative RT-PCR to measure 46 genes
that are expressed in hESCs, which function as cytokines, growth
factors, and other signaling molecules. In addition to analyzing
pluripotency gene expression in hESCs and hNSCs, we also
performed our analysis on human mesenchymal stem cells
(hMSCs), which are also considered to have a limited differenti-
ation potential. As depicted in a heat map format in Figure 1G,
most of the genes analyzed are expressed at higher levels in hESCs
compared to hNSCs or hMSCs, as expected. Interestingly, hNSCs
highly expressed receptors involved in STAT signal transduction
such as LIFR and IL6ST. Indeed, it has been demonstrated that
LIF promotes self-renewal of human neural stem cells in vitro,
though STAT signaling is insufficient to promote self-renewal in
hESCs [24–26]. In sum, analysis of genes involved in pluripotency
in hNSCs has revealed these cells are primed with several factors
such as SOX2, c-MYC, and KLF4, which might support more
readily their induction into a pluripotent state.
iPS Cells Can Be Generated from Human NSCs by
Exogenous Expression of OCT3/4 and KLF4
Since we observed robust expression of SOX2 and modest
expression of c-MYC and KLF4 in our human NSC cultures, we
tested if ectopic expression of OCT3/4 per se would be sufficient
to convert them from multipotent to pluripotent stem cells.
Furthermore, it was recently demonstrated that Oct3/4 expression
in mouse NSCs was sufficient to convert them into iPS cells,
suggesting this strategy might function in hNSCs. We infected
1610
6 hNSCs with OCT3/4 retrovirus, and after multiple
attempts and long incubation periods greater than two months,
we did not observe any colonies. This inability to reprogram
human NSCs with OCT3/4 alone might indicate possible
differences between mouse and human NSCs. To rule out
whether this might be due to low targeting efficiencies, we
performed immunocytochemistry against OCT3/4 and observed
an 80% infection rate (data not shown), suggesting this was not an
inability to deliver OCT3/4 to hNSCs. Since KLF4 has been
shown to play a critical role in chromatin remodeling and
maintaining self-renewal in hESCs [27,28], and it was shown to
support iPS cell induction in conjunction with Oct3/4 from mouse
NSCs [14,16], we introduced it into our iPS induction strategy.
We achieved a targeting efficiency of approximately 80% with
both retroviruses containing OCT3/4 and KLF4. The day after
retroviral transduction, cells were grown in NSC media for four
days following a change to hESC media to support iPS cell growth
(Figure 2A). Within ten days we observed localized areas of dense
cell growth and within three weeks, we observed cells that were
morphologically similar to hESCs (Figure 2B, C). Based on the
percentage of cells that were infected with both OCT3/4 and
KLF4 at 80%, we calculated our reprogramming efficiency to be
approximately 0.01% (80 colonies from 0.8610
6 cells infected with
both OCT3/4 and KLF4), which was elevenfold less efficient than
iPS induction from mouse NSCs with Oct3/4 and Klf4. This may
be due to lower endogenous expression of c-MYC in human NSCs
compared to mouse NSCs [14]. The efficiencies of reprogram-
ming human dermal and neonatal foreskin fibroblasts to iPS cells
utilizing OCT4, SOX2, KLF4, and c-MYC have been shown to
range between 0.01–0.02% [6,9,10,12] which is quite similar to
our reprogramming efficiencies on human NSCs with OCT3/4
and KLF4. We picked seven iPS clones that were morphologically
similar to hES cells, and of those three iPS lines were generated.
To verify whether the retroviral KLF4 and OCT3/4 transgenes
were present in our iPS clones, we performed PCR analysis and
observed both transgenes were integrated in all clones we analyzed
(Figure S1A). In addition, iPS cells stained positive for alkaline
phosphatase (AP) activity, which is a prototypical marker for ES
cells (Figure 2D). We also found expression of a wide panel of
markers expressed in hESCs in our iPS cells, which include
OCT3/4, SSEA-3, TRA-1-60, TRA-1-81, NANOG, KLF4, and
LIN28 (Figure 2E–M). In contrast, SSEA-1 staining was not
Figure 1. Human NSCs express several genes involved in the maintenance of pluripotency. Human NSCs express SOX2 and NESTIN (A)
and are tri-potent, which can differentiate into astrocytes shown by GFAP (green) and S100-Beta (red) staining (B), neurons shown by TUJ1 staining
(green) (C), and oligodendrocytes shown by O4 staining (green) (D). (E) Semi-quantitative RT-PCR analysis of key pluripotency genes expressed in
human ES cells and several lacking in human NSCs. (F) Quantitative RT-PCR analysis of key pluripotency genes in human NSCs relative to hESCs. (G)
Heat map derived from quantitative RT-PCR depicting relative expression of multiple genes associated with pluripotency comparing human MSCs,
NSCs, and ESCs.
doi:10.1371/journal.pone.0007044.g001
iPSCs from Human NSCs
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cells (Figure 2N). All iPS lines (iPS1-iPS3) showed the full
complement of pluripotency markers utilized.
To further confirm the authenticity of our iPS clones, we
performed quantitative RT-PCR on four major pluripotency
inducing genes, OCT3/4, KLF4, SOX2, and c-MYC, in three of
our iPSclones.We also performed qRT-PCR to determinewhether
the retroviral OCT3/4 and KLF4 transgenes were silenced, which
has been shown to be a reliable measure for efficient reprogram-
ming of somatic cells into pluripotency [29]. As shown in Figure 3A,
all iPS lines tested showed similar levels of these factors compared to
hESCcells.Inaddition,alllinesshowednearlycompletesilencingof
the transgenes for both OCT3/4 and KLF4 (Figure 3A).
A more stringent test was utilized to determine whether
reprogramming human NSCs was accompanied by demethylation
of the OCT3/4 and NANOG promoters, both of which must be
active to maintain pluripotency. To do this, we performed bisulfite
sequencing to evaluate the methylation status of these promoters
in several of our iPS lines. Consistent with our earlier findings
analyzing OCT3/4 and NANOG gene expression, both promot-
ers were hypermethylated and hypomethylated in hNSCs and
hESCs, respectively (Figure 3B). All of these data highly support
that iPS cells derived from hNSCs can be reprogrammed to a
hESC-like state at the molecular level. This reprogramming to an
ESC like state was also accompanied by an increase in
proliferation as shown by flow cytometry analysis (FACS).
Quantification of this data showed that hNSC-derived iPS cells
were more similar to hESCs in the percentage of cells in the
G2/M phase of the cell cycle than were hNSCs (Figure S1b). This
increase in proliferation was not due to transformation in culture
since karyotypic analysis of all iPS lines analyzed (iPS1-2) revealed
a normal number of chromosomes (46XX) without gross
abnormalities (Figure 3C).
Human NSC-derived iPS Cells Can Differentiate into All
Three Germ Lineages In vitro and In vivo
Pluripotent stem cells are capable of differentiating into all three
germ lineages of the human body, and we thus investigated the
developmental potential of our i-PS cells to determine whether they
could differentiate into ectoderm, endoderm, and mesoderm. We
differentiated our iPS cells as embryoid bodies (EB) (Figure 4A) in
the presence of FBS to induce endodermal and mesodermal fates,
and in the presence of retinoic acid to induce an ectodermal fate,
and after ten days allowed them to adhere to tissue culture dishes.
After the EBs adhered, we analyzed our cultures for different germ
layer markers by immunocytochemical analysis. As shown in
Figure4,allthreegermlayersdevelopedinourcultures asshown by
alphafetoprotein (AFP) for endoderm (Figure 4B), smooth muscle
actin (SMA)and desmin formesoderm (Figure4D,E),glial fibrillary
acid protein (GFAP) and SMI31 for ectoderm (Figure 4G, H). To
determine the in vivo developmental potential of our iPS lines, we
injected iPS-1 and iPS-3 lines into athymic nude mice to induce
teratomas. The teratomas analyzed were shown to contain muscle
tissues, which are derivatives of mesoderm, primitive duct
formations (indicated by arrows), which are derivatives of
endoderm, and epidermal structures, which are derivatives of
ectoderm (Figure 4C, F, I). All iPS lines tested (iPS1, 3) gave rise to
teratomas with all three germ layers. These data support the
developmental potential of the iPS cells showing that they have the
ability to give rise to all three cell lineages both in vitro and in vivo,
which are critical attributes of pluripotent stem cells.
Discussion
Here we have identified another source of human cells that can
be efficiently reprogrammed into human iPS cells by the ectopic
exposure of only two factors, namely OCT3/4 and KLF4. The
Figure 2. Human iPS cells can be generated from human NSCs. (A) Schematic depicting the strategy to induce pluripotency in human NSCs.
(B) After 21 days iPSC colonies emerge, which are molecularly indistinguishable from hESC colonies under low and high magnification (C) and stain
positive for alkaline phosphatase (D). (E–M) Extensive immunocytochemical analysis of genes expressed human NSC-derived iPS cells, which are also
expressed in hESCs except for SSEA-1 (N), which is only expressed in mouse ES cells.
doi:10.1371/journal.pone.0007044.g002
iPSCs from Human NSCs
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due to the intrinsic expression of SOX2 within human NSCs,
which has been shown to a major protein involved in maintaining
pluripotency in hESCs. It is interesting that OCT3/4 was not
sufficient to convert human NSCs into iPS cells utilizing our
techniques. This could reflect intrinsic differences between mouse
and human NSCs, but might still be attainable by altering some
experimental parameters such as infecting more target cells,
extending culturing conditions, and incubating target cells with a
rho-kinase inhibitor small molecule, shown to enhance survival of
human ES cells [30,31]. Through extensive examination, we have
shown that human NSC-derived iPS cells are phenotypically
identical to hESCs by all pluripotential markers analyzed and for
their ability to differentiate into all three major germ lineages.
The utilization of human NSCs as a potential source for
reprogramming into iPS cells offers multiple advantages. Since the
reprogramming process requires only two factors, the chance of
insertional mutagenesis is minimized. Furthermore, obviating the
Figure 3. Human NSC-derived iPS cells are genetically similar to hESCs. (A) Quantitiative RT-PCR analysis of key pluripotency inducing genes
from endogenous (shown as ‘‘E’’) loci or transgenic (shown as ‘‘T’’) loci normalized to hESC gene expression. (B) Bisulfite sequence analysis of the
human OCT3 and NANOG promoters in hESCs and multiple iPS clones. Unfilled or filled circles represent unmethylated or methylated CpGs,
respectively. (C) Karyotype analysis of multiple iPS clones.
doi:10.1371/journal.pone.0007044.g003
iPSCs from Human NSCs
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cells. In addition, since two factors are sufficient for human iPS
induction from NSCs, it may be possible to substitute one or both
of these factors with small molecules that activate OCT3/4 or
KLF4 gene expression. Indeed, a recent report has demonstrated
that the small molecule, kenpaullone could replace KLF4 in
reprogramming mouse fibroblasts into iPS cells [32]. This report
suggests it may be possible to reprogram human NSCs into iPS
cells by OCT3/4 and kenpaullone, further minimizing the
undesired effects of utilizing retroviral vectors. Another advantage
of utilizing human NSCs is that they endogenously express SOX2,
KLF4, and c-MYC, which provides a basis to analyze the
mechanism of iPS induction with two factors.
Research on induced pluripotency has been rapidly expand-
ing providing more efficient means to generate iPS cells.
Indeed, a plethora of research reports has implicated the master
guardian of the genome, p53, as being a major hindrance to the
iPS induction process [33–38]. By impairing the p53 pathway
on multiple levels, researchers were able to dramatically
enhance the iPS cell induction up to 100 fold. By impairing
the p53 pathway in hNSCs, it is probable that this will also
increase the rate of IPS cell induction from these cells. In sum,
human NSCs represent an invaluable source of cells to
investigate human iPS induction, and also represent a potential
source of cells for deriving patient-specific pluripotent stem cells
for modeling human disease.
Supporting Information
Figure S1 Multiple iPS lines show integration of both the
OCT3/4 and KLF4 transgenes and progress through the cell cycle
similarly to hESCs. (A) Genotype analysis of multiple iPS lines for
OCT3/4 and KLF4 transgenes. (B) FACs analysis of the cell cycle
in proliferating hNSCs, hESCs, and iPS cells with a chart showing
percentages of cell types in the G2/M phase of the cell cycle.
Supplemental Table 1. Information regarding the primary
antibodies utilized in immunofluorescence analysis and primers
utilized in RT-PCR, genotyping, and bisulfite sequencing
analyses.
Found at: doi:10.1371/journal.pone.0007044.s001 (0.95 MB TIF)
Table S1 Table S1. Information regarding the primary
antibodies utilized in immunofluorescence analysis and primers
utilized in RT-PCR, genotyping, and bisulfite sequencing
analyses.
Found at: doi:10.1371/journal.pone.0007044.s002 (0.05 MB
DOC)
Figure 4. Human NSC-derived iPS cells can form all three germ lineages both in vitro and in vivo. (A) iPS cells can form embryoid bodies
(EB) and can differentiate in vitro to endoderm shown by alpha fetoprotein (AFP) (B), mesoderm shown by smooth muscle actin (SMA) and desmin
(D,E), and ectoderm shown by GFAP and SMI31 staining (G,H). iPS cells injected into athymic nude mice form teratomas and differentiate into all germ
lineages in vivo (C,F,I).
doi:10.1371/journal.pone.0007044.g004
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